Key Developments: Baxter International Inc (BAX)

BAX on New York Consolidated

74.07USD
18 Dec 2014
Price Change (% chg)

$1.80 (+2.49%)
Prev Close
$72.27
Open
$73.19
Day's High
$74.08
Day's Low
$72.90
Volume
2,650,194
Avg. Vol
2,874,818
52-wk High
$77.31
52-wk Low
$65.82

Search Stocks

Latest Key Developments (Source: Significant Developments)

FDA advisory committee panel provides favorable recommendation on Baxter International Inc's HyQvia for primary immunodeficiency
Thursday, 31 Jul 2014 01:55pm EDT 

Baxter International Inc and Halozyme Therapeutics, Inc:Says Blood Products Advisory Committee (BPAC) of U.S. Food and Drug Administration (FDA) voted 15-1 that HyQvia [Immune Globulin Infusion 10 pct (Human) with Recombinant Human Hyaluronidase].Says Baxter's investigational subcutaneous treatment for patients with primary immunodeficiency (PI), has favorable risk/benefit profile.  Full Article

Baxter International Inc announces divestiture of commercial vaccines business to Pfizer Inc
Wednesday, 30 Jul 2014 08:02am EDT 

Baxter International Inc:Entered into a definitive agreement to sell its two commercially marketed vaccines and related production facilities to Pfizer Inc.For a total cash consideration of $635 million, subject to certain adjustments.  Full Article

Baxter International Inc declares quarterly dividend
Tuesday, 22 Jul 2014 09:00am EDT 

Baxter International Inc:Declares a quarterly dividend of $0.52 per share.Payable on Oct. 1 to shareholders of record as of Sept. 5.  Full Article

Baxter International Inc gives Q3 2014 outlook in line with analysts' estimates; raises FY 2014 outlook
Thursday, 17 Jul 2014 07:00am EDT 

Baxter International Inc:Expects Q3 2014 sales growth of about 12 to 13 percent, excluding the impact of foreign currency.Expects Q3 2014 earnings, before special items, of $1.28 to $1.32 per diluted share.Q3 2014 revenues of $4.12 bln and EPS of $1.32 - Thomson Reuters I/B/E/S.Expects FY 2014 sales growth of 10 to 11 percent, before the impact of foreign exchange.Expects FY 2014 earnings, before special items, of $5.10 to $5.20 per diluted share.The FY 2014 earnings guidance excludes the $0.62 per diluted share of special items comprising $0.49 per diluted share of items recorded in the first half of the year, and projected intangible asset amortization expense of $0.13 per diluted share for the remainder of the year.FY 2014 revenues of $16.63 bln and EPS of $5.15 - Thomson Reuters I/B/E/S.  Full Article

Baxter International Inc Names chief financial officers for new biopharmaceutical spin-off and Baxter International Inc
Monday, 7 Jul 2014 09:00am EDT 

Baxter International Inc:Says Robert J. Hombach, currently chief financial officer for Baxter International Inc., will be appointed chief financial officer and will assume additional operational responsibilities for the independent biopharmaceuticals company.James K. Saccaro will rejoin Baxter Aug. 4, and will assume the role of chief financial officer of Baxter International Inc., reporting to Robert L. Parkinson.  Full Article

Baxter International raises quarterly dividend
Monday, 5 May 2014 04:30pm EDT 

Baxter International Inc:Declares quarterly dividend of $0.52 per Baxter common share, representing a 6 pct increase.Payable on July 1 to shareholders of record as of June 6.  Full Article

Baxter International announces FDA approval of ADVATE with BAXJECT III reconstitution system
Wednesday, 23 Apr 2014 09:00am EDT 

Baxter International Inc:Says the U.S. Food and Drug Administration (FDA) has approved a new reconstitution system for ADVATE (Antihemophilic Factor [Recombinant]).ADVATE and the diluent come pre-packaged in the new BAXJECT III reconstitution system.Reconstitution system was developed to reduce the number of steps in reconstitution process for hemophilia A patients and caregivers, compared to the previous process with the BAXJECT II needle-less transfer device.  Full Article

Baxter International Inc gives Q2 2014 revenue outlook above analysts' estimates, Q2 2014 EPS outlook below analysts' estimates; reaffirms FY 2014 outlook
Thursday, 17 Apr 2014 07:00am EDT 

Baxter International Inc:Expects Q2 2014 sales growth of about 12 to 13 percent, excluding the impact of foreign currency.Expects Q2 2014 earnings, before special items, of $1.18 to $1.22 per diluted share.Q2 2014 earnings guidance excludes about $0.07 per diluted share of projected intangible asset amortization expense.The company reported revenue of $3.95 bln in Q1 2014.Q2 2014 revenues of $4.17 bln and EPS of $1.33 - Thomson Reuters I/B/E/S.Expects FY 2014 sales growth of 9 to 10 percent, before the impact of foreign exchange.FY 2014 earnings, before special items, of $5.05 to $5.25 per diluted share.FY 2014 earnings guidance excludes $0.38 per diluted share of special items comprising $0.18 per diluted share of items recorded in the Q1, and projected intangible asset amortization expense of $0.20 per diluted share for the remainder of the year.FY 2014 revenues of $16.60 bln and EPS of $5.13 - Thomson Reuters I/B/E/S.  Full Article

Baxter International invests to construct facility of $1 billion
Thursday, 17 Apr 2014 06:15am EDT 

Baxter International Inc:Decides to invest $1bln to construct a 1 mln-square-foot plasma fractionation facility with purification and fill/finish suites in Covington, Georgia.In support of the massive project, now under construction, the state is building the $14 mln Georgia BioScience Training Center adjacent to the new plant.  Full Article

Baxter International Inc meets primary efficacy endpoint in phase 3 trial of BAX 111, investigational stand-alone recombinant treatment for von willebrand disease
Wednesday, 16 Apr 2014 08:48am EDT 

Baxter International Inc:Announces topline results from a phase 3 clinical trial evaluating the safety, efficacy and pharmacokinetics (PK) of BAX 111.BAX 111 is a recombinant von Willebrand factor (rVWF) under investigation for the treatment of bleeding episodes in patients with von Willebrand disease, the most common type of inherited bleeding disorder.The primary endpoint was the number of patients experiencing successful treatment for bleeding episodes. Secondary endpoints included additional efficacy and safety measures, pharmacokinetics and health-related quality of life (HRQoL).  Full Article

BRIEF-Caverion provides building systems for Baxter in Austria

* Entered into a contract with pharmaceutical group Baxter in framework of a consortium with Molin

Search Stocks